



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

13

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,279	04/11/2006	Antonius G. P. Oomens	010.2039	9544
49837	7590	09/11/2007	EXAMINER	
LAWRENCE SUNGO- S2IPLAW, PLLC			BLUMEL, BENJAMIN P	
401 9TH STREET, NW			ART UNIT	PAPER NUMBER
SUITE 900-NIXON PEABODY LLP			1648	
WASHINGTON, DC 20004-2128				

MAIL DATE	DELIVERY MODE
09/11/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10575279	4/11/2006	OOMENS ET AL.	010.2039

EXAMINER

Benjamin P. Blumel

ART UNIT	PAPER
----------	-------


1648 20070824


DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

Commissioner for Patents

The reply filed on June 15, 2007 is not fully responsive to the prior Office action because of the following omission(s) or matter(s): an election of group B does not satisfy the requirement for an election of a species as required by the Office action of May 15, 2007. In order to be fully compliant with the election of species requirement, as stated on page 3, lines 10-11 of the prior Office action, applicants must elect a specific species (unless stated otherwise) from each grouping also stated on page 3. For example, group A requires a specific non-paramyxoviral envelope protein composition of claim 58 (i.e. an ectodomain and a transmembrane domain of the baculovirus GP64 protein and a C-terminal sequence of a respiratory syncytial virus fusion protein F, or the baculovirus GP64 protein). The applicants are notified that any claims not reading on the elected invention/species will be withdrawn from consideration. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

  
Benjamin Blumel  
Patent Examiner



BRUCE R. CAMPELL, PH.D  
SUPERVISORY PATENT EXAMINER,  
TECHNOLOGY CENTER 1600